M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 21 of 54
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
NCT00756639
Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer
NCT00791635
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
NCT00715442
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
NCT00707473
Literacy and Smoking Risk Communications
NCT00684437
Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations
NCT00648635
Lifestyle Intervention for Heart Failure
NCT00633633
Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting
NCT00618553
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
NCT00567684
Home-Based Measures of Physical Activity and Body Composition
NCT00542438
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
NCT00542373
Smoking Cessation for Depressed Smokers
NCT00494728
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT00494182
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
NCT00488072
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
NCT00479128
Proton Beam Therapy for Chordoma Patients
NCT00496119
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
NCT00492050
Brachytherapy for Prostatic Carcinoma Patients
NCT00525720
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
NCT00329043
Proton Beam Therapy for Chondrosarcoma
NCT00496522
Dexamethasone for Symptom Burden in Advanced Cancer Patients
NCT00489307
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
NCT00338377
Depression and Adherence in Head and Neck Cancer
NCT00498875
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
NCT00102648
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
NCT00076310
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
NCT00082706
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
NCT01439659
Depression Treatment and Screening in Ovarian Cancer Patients
NCT00515372
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
NCT00508443
Alopecia Areata Registry
NCT00069589
Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2
NCT03048279
Genetic Susceptibility to Bladder Cancer
NCT00848289
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
NCT07053020
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
NCT07137481
Wearable Device Tracked Recovery From Autologous Breast Reconstructive Surgery
NCT07631026
Phase 1 Study Of KITE-753 in R/R B-Cell ALL
NCT07674823
Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions
NCT07631013
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
NCT07674810
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
NCT07604233
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
NCT07579221
Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas
NCT07649070
Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
NCT07655570
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (≥ 10% Blasts) With TP53 Mutations
NCT07646821
Oncologic Timely Palliative Care And Remote Monitoring With Electronic Assessments And Telehealth (ON-TARGET)
NCT07674797
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
NCT07283640
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
NCT07610525
Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer
NCT04181463
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
NCT07227909
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT07269470
Creating Opportunities For Personal Empowerment (COPE) In Women With Breast Cancer During First-Line Therapy: A Pilot Randomized Controlled Trial
NCT07610499
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.